Related Experiment Video
Updated: Jun 6, 2026
05:53
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
Evaluating a newly developed pharmacogenetic array: screening in a Spanish population
Berta Almoguera1, Rosa Riveiro-Alvarez, Belen Gomez-Dominguez
1Genetics Department, CAIBER Unit, IIS-Fundacion Jimenez Diaz, Madrid, Spain and CIBERER ISCIII, Madrid, Spain.
Pharmacogenomics
|December 3, 2010
Summary
PHARMAChip(®) demonstrates high accuracy (94.8%) and genotyping success (99.6%) for pharmacogenetic testing. Its validated performance supports its use in clinical settings, highlighting the need for population-specific genetic data.
Area of Science:
- Pharmacogenomics
- Molecular Diagnostics
- Genetics
Background:
- Understanding gene-drug interactions is crucial for personalized medicine.
- Validation of novel pharmacogenetic technologies is essential.
- Population-specific genetic frequencies impact drug response.
Purpose of the Study:
- To determine the analytical performance of the PHARMAChip(®) array.
- To establish Spanish population allelic and genotypic frequencies for 90 pharmacogenetic variants.
- To compare Spanish frequencies with existing Caucasian data.
Main Methods:
- Assessed sensitivity, specificity, and accuracy of PHARMAChip(®) for CYP2D6 and SLC6A4.
- Determined genotyping success rate across 90 pharmacogenetic variants in 36 genes.
- Analyzed data from 449 Spanish subjects.
Main Results:
- Sensitivity and specificity ranged from 96-100%.
- Accuracy for SLC6A4 was 94.8%.
- Genotyping success rate reached 99.6%.
Conclusions:
- PHARMAChip(®) is an accurate, rapid, and updatable tool for pharmacogenetic testing, particularly for cytochrome P450 variants.
- Spanish population genetic frequencies differ, emphasizing the need for intraethnic considerations.
- Validated pharmacogenetic arrays are vital for advancing personalized medicine.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
02:46Genetic Screens
Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing genetic diseases and help them with early intervention, targeted therapy, and reproductive options.
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which result in visible changes...
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which result in visible changes...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...